Barclays reaffirmed their hold rating on shares of Integra Lifesciences (NASDAQ:IART) in a research note published on Tuesday. Barclays currently has a $53.00 price objective on the life sciences company’s stock.

Other equities analysts have also issued reports about the stock. Oppenheimer reaffirmed a buy rating and set a $60.00 target price on shares of Integra Lifesciences in a research report on Monday, September 18th. Zacks Investment Research lowered shares of Integra Lifesciences from a buy rating to a hold rating in a research report on Wednesday, October 25th. Jefferies Group reaffirmed a buy rating and set a $58.00 target price on shares of Integra Lifesciences in a research report on Thursday, October 12th. UBS Group reaffirmed a buy rating and set a $57.00 target price on shares of Integra Lifesciences in a research report on Tuesday, October 31st. Finally, Wells Fargo & Co lowered shares of Integra Lifesciences from an outperform rating to a market perform rating in a research report on Sunday, October 29th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. Integra Lifesciences has a consensus rating of Hold and a consensus price target of $52.70.

Shares of Integra Lifesciences (IART) traded up $0.10 during midday trading on Tuesday, reaching $50.57. 352,799 shares of the company’s stock traded hands, compared to its average volume of 505,972. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $3,960.76, a P/E ratio of 82.90, a P/E/G ratio of 1.68 and a beta of 0.65. Integra Lifesciences has a twelve month low of $40.51 and a twelve month high of $56.42.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). The firm had revenue of $278.83 million during the quarter, compared to the consensus estimate of $286.00 million. Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.93 EPS. research analysts predict that Integra Lifesciences will post 1.85 earnings per share for the current fiscal year.

In other Integra Lifesciences news, Director Barbara B. Hill acquired 10,768 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, with a total value of $502,434.88. Following the completion of the acquisition, the director now directly owns 55,540 shares in the company, valued at approximately $2,591,496.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Richard D. Gorelick sold 1,500 shares of Integra Lifesciences stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The disclosure for this sale can be found here. Company insiders own 21.50% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. increased its holdings in Integra Lifesciences by 3.3% during the third quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock valued at $5,343,000 after buying an additional 3,340 shares during the period. Jennison Associates LLC increased its holdings in Integra Lifesciences by 48.3% during the third quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock valued at $52,232,000 after buying an additional 336,930 shares during the period. Ameriprise Financial Inc. grew its holdings in Integra Lifesciences by 2.9% in the second quarter. Ameriprise Financial Inc. now owns 434,993 shares of the life sciences company’s stock worth $23,709,000 after purchasing an additional 12,212 shares during the last quarter. Royal Bank of Canada grew its holdings in Integra Lifesciences by 21.4% in the second quarter. Royal Bank of Canada now owns 1,072,799 shares of the life sciences company’s stock worth $58,477,000 after purchasing an additional 188,893 shares during the last quarter. Finally, First Trust Advisors LP grew its holdings in Integra Lifesciences by 216.1% in the third quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock worth $2,579,000 after purchasing an additional 34,925 shares during the last quarter. 87.58% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Integra Lifesciences (IART) Rating Reiterated by Barclays” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/integra-lifesciences-iart-rating-reiterated-by-barclays/1805893.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.